1. Home
  2. Clinical Topics
  3. FDA warns of potential risk of liver injury in ADPKD patients taking Samsca
Clinical TopicsDrugs and DevicesHealthcare & TechnologyPatient SafetyWeb ExclusivesWorkplace Management

FDA warns of potential risk of liver injury in ADPKD patients taking Samsca

Share

On Jan. 25, 2013, the U.S. Food and Drug Administration notified healthcare professionals of significant liver injury associated with the use of Samsca in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). In a double-blind, 3-year, placebo-controlled trial in about 1400 patients with ADPKD and its open-label extension trial, three patients treated with the drug developed significant increases in serum alanine aminotransferase (ALT) with clinically significant increases in serum total bilirubin. Healthcare providers should perform liver tests promptly in patients who report symptoms that may indicate liver injury, and if injury is suspected, Samsca should be discontinued. Read more.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts